Takamune Nobutoki

タカムネノブトキ | Takamune Nobutoki

Affiliation and department：

Research field (1)： Pharmaceuticals - health and biochemistry

Research theme for competitive and other funds (20)：

2022 - 2025 Development of novel HIV-1 capsid (CA) inhibitors, and determination regarding novel mechanism of CA uncoating
2019 - 2022 Development of basic technology for creating mucosal vaccines using unique medium-chain fatty acids secreted by worker bees
2018 - 2021 Fundamental study of NER mechanism aiming to develop a novel HIV therapy in next generation
2015 - 2018 Investigation of novel expression mechanism of HIV pathogenic protein to develop the next generation HIV therapy
2015 - 2018 Prevention of a virus propagation based on cellular factors controlling HIV infection

2015 - 2017 Development and application of M-cell targeting new adjuvant for mucosal immunization

2012 - 2015 Study to develop novel anti-HIV strategy targeting to weak point of HIV life cycle

2012 - 2015 Exploration of cellular host factor required for HIV-1 infection and approaches to overcome multi-drug resistant HIV-1

2010 - 2011 New strategy for inhibition of HIV replication by targeting to NMT1 without appearance of drug resistant virus

2009 - 2011 Development of the next generation of AIDS vaccine candidates based on the immune response of HIV-resistant individuals.

2008 - 2009 Strategy for inhibition of HIV-1 replication without appearance of drug resistant virus and attenuation of the virus

2004 - 2006 Development of HIV-1 coreceptor-based HIV /AIDS defense vaccine

2004 - 2005 HIV-1コレセプターの特殊立体構造に対する分子認識自己抗体誘導によるエイズ制御

2004 - 2004 ヒト型HIV感染防御抗体・ヒト型エイズ発症防止抗体の創製のための生化学的基礎研究

2003 - 2003 HIV-1コレセプターの特殊立体構造に対する分子認識自己抗体誘導によるエイズ制御

2002 - 2003 HIV-1感染細胞が誘導する神経細胞死のプロテオーム解析

2002 - 2002 HIV-1コレセプターの特殊構造に対する立体特異的自己抗体誘導によるエイズ制御

2001 - 2001 耐性ウイルスに有効な抗HIV薬及びコレセプターを基礎にした感染防御法の開発

2000 - 2000 耐性ウイルスに有効な抗HIV薬及びコレセプターを基礎にしたワクチンの開発

1999 - 2000 DISCOVERY OF SUICIDE PEPTIDE-INHIBITOR OF HIV-1 PROTEASE

Show all

Papers (60)：

Shin-ichiro Hattori, Haydar Bulut, Hironori Hayashi, Naoki Kishimoto, Nobutoki Takamune, Kazuya Hasegawa, Yuri Furusawa, Seiya Yamayoshi, Kazutaka Murayama, Hirokazu Tamamura, et al. Structural and virologic mechanism of the emergence of resistance to M ^pro inhibitors in SARS-CoV-2. Proceedings of the National Academy of Sciences. 2024. 121. 37
Tomofumi Nakamura, Mayu Okumura, Nobutoki Takamune, Tatsunori Hirotsu, Masaharu Sugiura, Junichiro Yasunaga, Hirotomo Nakata. Conversion of raltegravir carrying a 1,3,4-oxadiazole ring to a hydrolysis product upon pH changes decreases its antiviral activity. PNAS nexus. 2024. 3. 1. pgad446
鍬田伸好, 辻耕平, 林宏典, 石井貴大, 小早川拓也, 中野堅太, 服部真一朗, 岸本直樹, 高宗暢暁, 青木宏美, et al. 抗SARS-CoV-2メインプロテアーゼ阻害剤の創薬研究開発. 日本エイズ学会誌. 2023. 25. 4. 428-428
鍬田伸好, 辻耕平, 林宏典, 石井貴大, 小早川拓也, 中野堅太, 服部真一朗, 岸本直樹, 高宗暢暁, 青木宏美, et al. 抗SARS-CoV-2メインプロテアーゼ阻害剤の創薬研究開発. 日本エイズ学会誌. 2023. 25. 4. 428-428
中村朋文, 奥村真由, 高宗暢暁, 弘津辰徳, 杉浦正晴, 安永純一朗, 中田浩智. 1,3,4-oxadiazole環を有するRaltegravirは強酸性下で加水分解され、抗HIV活性が低下する. 日本エイズ学会誌. 2023. 25. 4. 480-480

ｍore...

MISC (7)：

篠原功紀, 鍬田伸好, 辻耕平, 石井貴大, 小早川拓也, 服部真一朗, 岸本直樹, 高宗暢暁, 三隅将吾, HAYDAR Bulut, et al. Development of small molecule inhibitors with potent antiviral activity targeting SARS-CoV-2 main protease. 日本薬学会年会要旨集(Web). 2024. 144th
篠原功紀, 鍬田伸好, 辻耕平, 石井貴大, 小早川拓也, 服部真一朗, 岸本直樹, 高宗暢暁, 三隅将吾, BULUT Haydar, et al. フッ素化及びチオアミド置換を活用した新規SARS-CoV-2メインプロテアーゼ阻害剤の創製. 日本薬学会関東支部大会講演要旨集(CD-ROM). 2023. 67th
篠原功紀, 鍬田伸好, 辻耕平, 石井貴大, 小早川拓也, 服部真一朗, 岸本直樹, 高宗暢暁, 三隅将吾, BULUT Haydar, et al. Development of SARS-CoV-2 Main Protease Inhibitors by Fluorine Substitution and Amide Bond Conversion. 日本薬学会年会要旨集(Web). 2023. 143rd
服部真一朗, BULUT Haydar, 岸本直樹, 高宗暢暁, 鍬田伸好, 玉村啓和, 満屋裕明, 満屋裕明, 満屋裕明. ニルマトレルビルとその誘導体に耐性を示すSARS-CoV-2変異株の誘導と耐性獲得機序の解明. 日本エイズ学会誌. 2023. 25. 4
三隅将吾, 高宗暢暁, 庄司省三. HIV受容体をターゲットとするHIV感染防御ワクチン : 飲むエイズワクチンを目指して. ファルマシア. 2007. 43. 4. 327-331

ｍore...

Professional career (1)：

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page